Cardiotoxicity monitoring of pyrotinib in combination with nab-paclitaxel, doxorubicin, and cyclophosphamide in HER2-positive breast cancer: a single-armed clinical trial | Zendy

Wei Wang | Zendy; Lu Wang | Zendy; Jin-Yi Chang | Zendy; Fen Hu | Zendy; Jin-Yin Yan | Zendy; Juan Zhang | Zendy; Yong-Ping Liang | Zendy; Huiwen Zhang | Zendy; Hongpeng Wu | Zendy; Haifeng Cai | Zendy

Open Access

Cardiotoxicity monitoring of pyrotinib in combination with nab-paclitaxel, doxorubicin, and cyclophosphamide in HER2-positive breast cancer: a single-armed clinical trial

Author(s) -

Wei Wang,

Lu Wang,

Jin-Yi Chang,

Fen Hu,

Jin-Yin Yan,

Juan Zhang,

Yong-Ping Liang,

Huiwen Zhang,

Hongpeng Wu,

Haifeng Cai

Publication year - 2022

Publication title -

gland surgery

Language(s) - English

Resource type - Journals

eISSN - 2227-8575

pISSN - 2227-684X

DOI - 10.21037/gs-22-161

Subject(s) - medicine , cardiotoxicity , breast cancer , ejection fraction , cyclophosphamide , trastuzumab , regimen , oncology , cancer , chemotherapy , gastroenterology , heart failure

Human epidermal growth factor receptor 2 (HER2) inhibitors play a vital role in the treatment of HER2-positive breast cancer. Numerous studies have shown that traditional HER2 inhibitors and chemotherapeutics such as albumin-paclitaxel, liposomal doxorubicin, and cyclophosphamide (TAC regimen) have different degrees of cardiotoxicity. Pyrotinib is a novel small-molecule HER2 inhibitor and has no cardiotoxicity. Here, the purpose of this study was to investigate the cardiac safety of pyrotinib with TAC regimen for HER2-positive breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research